IMJUDO® (Tremelimumab) in Combinationq with IMFINZI® (Durvalumab) Approved in the US for Patients with Unresectable Liver Cancer

AstraZeneca’s Imjudo in combination with Imfinzi has been approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma, the most common type of liver cancer.